NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01772472,A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE),https://clinicaltrials.gov/study/NCT01772472,,COMPLETED,"This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in the breast or axillary lymph nodes following preoperative therapy. Eligible patients will be randomized to receive either trastuzumab emtansine 3.6 mg/kg or trastuzumab 6 mg/kg intravenously every 3 weeks for 14 cycles. Radiotherapy and/or hormone therapy will be given in addition if indicated.",YES,Breast Cancer,DRUG: trastuzumab|DRUG: trastuzumab emtansine,"Invasive Disease-free Survival (IDFS), IDFS event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion); ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast); distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned sites); death attributable to any cause; contralateral invasive breast cancer. 3-year IDFS event-free rate per randomized treatment arms in the ITT population were estimated using the Kaplan-Meier method and estimated the probability of a patient being event-free after 3 years after randomization., From randomization to data cut-off date of 25 July 2018 (approximately up to 64 months)","Invasive Disease-free Survival Including Second Primary Non-breast Cancer, IDFS including second primary non-breast cancer was defined the same way as IDFS for the primary endpoint but including second primary non breast invasive cancer as an event (with the exception of non-melanoma skin cancers and carcinoma in situ (CIS) of any site). 3-year IDFS including second primary non-breast cancer event-free rates per treatment arm in the ITT population were estimated using the Kaplan-Meier method and estimated the probability of a patient being event-free after 3 years after randomization., From baseline up to 12 years|Disease-free Survival, Disease-free survival was defined as the time between randomization and the date of the first occurrence of an invasive disease-free survival event including second primary non-breast cancer event or contralateral or ipsilateral DCIS. 3-year DFS event-free rates per randomized treatment arms in the ITT population were estimated using the Kaplan-Meier method and estimated the probability of a patient being event-free after 3 years after randomization., From baseline up to 12 years|Overall Survival (OS), Overall survival in the overall study population was defined as the time from the date of randomization to the date of death from any cause. 5 years OS event-free rate per randomized treatment arms in the ITT population were estimated using the Kaplan-Meier method and estimated the probability of a patient being event-free after 5 years after treatment., Baseline up to 12 years|Distant Recurrence-Free Interval (DRFI), DRFI was defined as the time between randomization and the date of distant breast cancer recurrence. 3 years DRFI event-free rate per randomized treatment arms in the ITT population were estimated using the Kaplan-Meier method and estimated the probability of a patient being event-free after 3 years after treatment., Baseline up to 12 years|Percentage of Participants With Adverse Events, An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs, including AEs of Special Interest and AEs of Particular Interest, were reported based on the national cancer institute common terminology criteria for AEs, Version 4.0 (NCI-CTCAE, v4.0). Reported are the number of subjects with AEs, Grade 3-5 AEs, and Serious Adverse Events (SAEs)., From Day 1 to 30 days after last dose of study drug, up to the clinical cutoff date (approximately 64 months)|Percentage of Participants With Cardiac Dysfunction, Cardiac events were reported based on the NCI-CTCAE, v4.0., From baseline up to 12 years|Change From Baseline of Functional Scales, Symptom Scales and Single Items in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30), The EORTC QLQ-C30 included global health status, functional scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea/vomiting, and pain) and single items (dyspnoea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Most questions used a 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores were averaged and transformed to 0 - 100 scale, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be a minimally important difference to participants. A positive value means an increase, while a negative value means a decrease, in score at the indicated time-point relative to the score at baseline (Cycle 1, Day 1)., Baseline, Cycle 5, 11, Follow-up (FU) Month 6, Follow-up Month 12|Change From Baseline of Four Functioning Scales and Four Symptom Scales in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Breast Cancer (QLQ-BR23), EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual enjoyment, sexual functioning, future perspective \[FP\]) and four symptom scales (systemic side effects \[SE\], upset by hair loss, arm symptoms, breast symptoms). Questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores averaged and transformed to 0-100 scale. High score for functional scale indicated high/better level of functioning/healthy functioning. Higher scores for symptom scales represent higher levels of symptoms/problems. For functional scales, positive change from baseline indicated deterioration in quality of life (QOL) and negative change from baseline indicated an improvement in QOL. For symptom scales, positive change from baseline indicated an improvement in quality of life (QOL) and negative change from baseline indicated a deterioration in QOL., Baseline, Cycle 5, 11, Follow-up Month 6, Follow-up Month 12|Serum Concentrations (Area Under the Concentration-time Curve [AUC]) of Trastuzumab Emtansine (Including Total Trastuzumab and DM1), Blood and serum samples for measurement of trastuzumab emtansine, total trastuzumab, and DM1 will be obtained from patients randomized to the trastuzumab emtansine arm., Cycle (C) 1, Day (D) 1 and C4D1 of pre-infusion, C1D1 and C4D1 post-infusion, C2D1 and C5D1 pre-infusion and study treatment termination|Serum Concentrations (AUC) of Trastuzumab, Serum blood samples were collected for trastuzumab measurement prior to dosing and 15-30 minutes post infusion for Cycle 1 and Cycle 4. Additional serum samples were collected at study treatment termination., C1D1 and C4D1 of post-infusion and study treatment termination|Plasma Concentrations of DM1, Day 1 on Cycles 1 and 4. Each cycle is 21 days.|Trastuzumab Emtansine Exposure, Day 1 on Cycles 1, 2, 4 and 5, at study treatment termination and 3-4 months after last dose of trastuzumab emtansine. Each cycle is 21 days.|Anti-trastuzumab Emtansine Antibody (ATA), Day 1 on Cycles 1, and 4, at study treatment termination and 3-4 months after last dose of trastuzumab emtansine. Each cycle is 21 days.|Anti-trastuzumab Antibody (ATA), Day 1 on Cycles 1, and 4, at study treatment termination and 3-4 months after last dose of trastuzumab emtansine. Each cycle is 21 days.",,Hoffmann-La Roche,NSABP Foundation Inc|GBG Forschungs GmbH,ALL,"ADULT, OLDER_ADULT",PHASE3,1487,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,BO27938|2012-002018-37,2013-04-03,2018-07-25,2024-05-23,2013-01-21,2019-10-01,2025-03-25,"Providence Alaska Medical Center, Anchorage, Alaska, 99508, United States|Todd Cancer Institute at Long Beach Memorial Medical Center, Long Beach, California, 90806, United States|Chao Family Comprehensive Cancer Center, Orange, California, 92868, United States|Stanford University Medical Center, Palo Alto, California, 94304, United States|Kaiser Permanente - San Diego, San Diego, California, 92120, United States|Breastlink Medical Group Inc, Santa Ana, California, 92705, United States|Kaiser Permanente - Vallejo, Vallejo, California, 94589, United States|Kaiser Permanente - Franklin, Denver, Colorado, 80205, United States|Colorado Cancer Research Program/Admin, Denver, Colorado, 80222, United States|Yale Cancer Center, New Haven, Connecticut, 06510-3221, United States|Washington Cancer Institute, Washington, District of Columbia, 20010, United States|University of Florida, Gainesville, Florida, 32610, United States|Mount Sinai Medical Center, Miami Beach, Florida, 33140, United States|UF Health Orlando, Orlando, Florida, 32806, United States|Moffitt Cancer Center, Tampa, Florida, 33612-9497, United States|Rush University Medical Center, Chicago, Illinois, 60612, United States|Edward Cancer Center Naperville, Naperville, Illinois, 60540, United States|Edward Cancer Center Plainfield, Plainfield, Illinois, 60585, United States|University of Iowa, Iowa City, Iowa, 52242, United States|University of Kentucky Medical Center, Lexington, Kentucky, 40536, United States|Norton Healthcare Inc., Louisville, Kentucky, 40202, United States|Cancer Care of Maine, Brewer, Maine, 04412, United States|New England Cancer Specialists, Scarborough, Maine, 04074, United States|Mercy Medical Center, Baltimore, Maryland, 21202, United States|Greater Baltimore Medical Center, Baltimore, Maryland, 21204, United States|Med Star Franklin Square Medical Center/Weinburg Cancer Institute, Baltimore, Maryland, 21237, United States|Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|Spectrum Health Hospitals, Grand Rapids, Michigan, 49503, United States|Breslin Cancer Center, Lansing, Michigan, 48910, United States|William Beaumont Hospital, Royal Oak, Michigan, 48073, United States|US oncology research at Minnesota Oncology, Saint Louis Park, Minnesota, 55426, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08903, United States|Sparta Cancer Center, Sparta, New Jersey, 07871-1791, United States|Columbia University Medical Center, New York, New York, 10032, United States|Troy Cancer Treatment Program, Troy, New York, 12180, United States|Carolinas Medical Center, Charlotte, North Carolina, 28204-2839, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, 58122-9988, United States|Aultman Hospital, Canton, Ohio, 44710, United States|Fairview Hospital, Cleveland, Ohio, 44111, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Ohio State University, Arthur James Cancer Hospital, Columbus, Ohio, 43210, United States|Columbia River Oncology Program, Portland, Oregon, 97225, United States|Kimmel Cancer Center Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States|Allegheny Cancer Center, Pittsburgh, Pennsylvania, 15212, United States|Uni of Pittsburgh, Pittsburgh, Pennsylvania, 15213, United States|York Hospital, York, Pennsylvania, 17403, United States|Medical University of South Carolina, Charleston, South Carolina, 29425, United States|Avera Cancer Institute, Sioux Falls, South Dakota, 57105, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, 37916-2305, United States|Baylor College of Medicine, Houston, Texas, 77030, United States|Houston Methodist Hospital Outpatient Center, Houston, Texas, 77030, United States|Uni of Texas - Md Anderson Cancer Center, Houston, Texas, 77030, United States|Joe Arrington Cancer Research & Treatment Center, Lubbock, Texas, 79410, United States|Hematology Oncology Associates of Fredericksburg, Inc., Fredericksburg, Virginia, 22408, United States|Centra Alan B. Pearson Regional Cancer Center, Lynchburg, Virginia, 24501, United States|Virginia Commonwealth University - Massey Cancer Center, Richmond, Virginia, 23298, United States|Swedish Cancer Institute - Issaquah, Issaquah, Washington, 98029, United States|Cancer Care Northwest, Spokane, Washington, 99204, United States|Marshfield Clinic, Marshfield, Wisconsin, 54449, United States|Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, C1125ABD, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, F5300COE, Argentina|Instituto de Oncología de Rosario, Rosario, S2000KZE, Argentina|Tiroler Landeskrankenanstalten Ges.M.B.H., Innsbruck, 6020, Austria|Lkh Salzburg - Univ. Klinikum Salzburg, Salzburg, 5020, Austria|Medizinische Universität Wien, Wien, 1090, Austria|Cliniques Universitaires St-Luc, Bruxelles, 1200, Belgium|AZ Sint Lucas (Sint Lucas), Gent, 9000, Belgium|CHU Sart-Tilman, Liège, 4000, Belgium|Sint Augustinus Wilrijk, Wilrijk, 2610, Belgium|Iop Instituto de Oncologia Do Parana, Curitiba, Paraná, 80530-010, Brazil|UPCO - Unidade de Pesquisas Clínicas em Oncologia, Pelotas, Rio Grande Do Sul, 96015-280, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, 90035-001, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, Rio Grande Do Sul, 91350-200, Brazil|Hospital de Cancer de Barretos, Barretos, São Paulo, 14784-400, Brazil|Instituto de Ensino e Pesquisa Sao Lucas - IEP, Sao Paulo, São Paulo, 01236-030, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, São Paulo, 01246-000, Brazil|Hospital Perola Byington, Sao Paulo, São Paulo, 01317-000, Brazil|Instituto Nacional de Cancer - INCa, Rio de Janeiro, 20560-120, Brazil|Clinicas Oncologicas Integradas - COI, Rio De Janeiro, 22290-160, Brazil|Arthur J.E. Child Comprehensive Cancer Center, Calgary, Alberta, T2N 4N2, Canada|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|BC Cancer ? Surrey, Surrey, British Columbia, V3V 1Z2, Canada|British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre, Vancouver, British Columbia, V5Z 4E6, Canada|London Regional Cancer Centre, London, Ontario, N6A 4L6, Canada|The Ottawa Hospital, Ottawa, Ontario, K1H 8L6, Canada|Princess Margaret Cancer Center, Toronto, Ontario, M5G 1Z5, Canada|CSSS champlain - Charles-Le Moyne, Greenfield Park, Quebec, J4V 2H1, Canada|Centre Hospitalier de l?Université de Montréal (CHUM), Montreal, Quebec, H2X 3E4, Canada|Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada|McGill University Health Centre - Glen Site, Montreal, Quebec, H4A 3J1, Canada|Hopital du Saint Sacrement, Quebec City, Quebec, G1J 1Z4, Canada|the First Hospital of Jilin University, Changchun, 130021, China|Sun Yet-sen University Cancer Center, Guangzhou, 510060, China|Guangdong General Hospital, Guangzhou, 510080, China|Harbin Medical University Cancer Hospital, Harbin, 150081, China|Shandong Cancer Hospital, Jinan, 250117, China|Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital), Shanghai, 200025, China|Fudan University Shanghai Cancer Center, Shanghai, 200032, China|Clinica del Country, Bogota, 11001, Colombia|Hospital Pablo Tobon Uribe, Medellin-Antioquia, Colombia|Oncomedica S.A., Monteria, DUMMY_VALUE, Colombia|Fakultni Nemocnice Hradec Kralove, Hradec Kralove, 500 05, Czechia|Fakultni nemocnice Olomouc, Olomouc, 779 00, Czechia|Vseobecna fakultni nemocnice v Praze, Praha, 128 08, Czechia|Institut Sainte Catherine, Avignon, 84918, France|Hopital Jean Minjoz, Besancon, 25030, France|Institut Bergonie, Bordeaux, 33076, France|Centre Hospitalier Fleyriat, Bourg En Bresse, 01012, France|Centre Francois Baclesse, Caen, 14076, France|Centre Jean Perrin, Clermont Ferrand, 63011, France|Centre de Cancerologie de la Sarthe, Clinique Victor HugoSoReCOH, Le Mans, 72000, France|Institut Paoli Calmettes, Marseille, 13273, France|Centre Val Aurelle Paul Lamarque, Montpellier, 34298, France|Institut Curie, Paris, 75231, France|Hopital Saint Louis, Paris, 75475, France|Hopital Tenon, Paris, 75970, France|Centre Henri Becquerel, Rouen, 76038, France|Centre Rene Huguenin, St Cloud, 92210, France|Centre Paul Strauss, Strasbourg, 67065, France|Institut Gustave Roussy, Villejuif, 94805, France|Hämatologie Onkologie im Zentrum MVZ GmbH, Augsburg, 86150, Germany|Praxisklinik Krebsheilkunde für Frauen / Brustzentrum (Dres. Kittel/Klare), Berlin-Lichtenberg, 10367, Germany|Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, 10707, Germany|HELIOS Klinikum Berlin-Buch, Berlin, 13125, Germany|Studienzentrum Berlin City, Berlin, 14169, Germany|Onkologische Schwerpunktpraxis Bielefeld, Bielefeld, 33604, Germany|Klinikum Sindelfingen-Böblingen, Böblingen, 71032, Germany|St. Johannes-Hospital, Dortmund, 44137, Germany|Luisenkrankenhaus GmbH & Co. KG., Brustzentrum, Düsseldorf, 40235, Germany|Universitätsklinikum Erlangen, Erlangen, 91054, Germany|Universitätsklinikum Essen, Essen, 45122, Germany|Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH, Essen, 45136, Germany|Klinikum Esslingen, Esslingen, 73730, Germany|Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt am Main, 60389, Germany|Klinik Johann Wolfgang von Goethe Uni, Frankfurt, 60596, Germany|Universitätsklinikum Freiburg, Freiburg, 79106, Germany|Evangelische Kliniken Gelsenkirchen GmbH, Gelsenkirchen, 45879, Germany|Universitätsklinikum Greifswald, Greifswald, 17475, Germany|Universitätsklinikum Halle (Saale), Halle, 06097, Germany|Krankenhaus St. Elisabeth und St. Barbara, Klinik für Frauenheilkunde und Geburtshilfe, Halle, 06110, Germany|Kooperatives Mammazentrum Hamburg Krankenhaus Jerusalem, Hamburg, 20357, Germany|St. Barbara-Klinik Hamm-Heessen GmbH, Hamm, 59073, Germany|Diakovere Henriettenstift, Frauenklinik, Hannover, 30559, Germany|Medizinische Hochschule Hannover, Klinik für Frauenheilkunde und Geburtshilfe, Hannover, 30625, Germany|Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg, 69120, Germany|Elisabeth-Krankenhaus Brustzentrum, Kassel, 34117, Germany|Klinikum Kassel GmbH, Kassel, 34125, Germany|UNI-Klinikum Campus Kiel Klinik für Gynäkologie und Geburtshilfe, Kiel, 24105, Germany|St. Elisabeth Krankenhaus Köln GmbH, Koeln, 50935, Germany|Kliniken der Stadt Köln gGmbH Krankenhaus Holweide, Köln, 51067, Germany|Gemeinschaftspraxis für Hämatologie und Onkologie, PD Dr. Bauer, Dr. Thiel, Lebach, 66822, Germany|Klinikum der Universität München, München, 80337, Germany|Medizinisches Zentrum für Hämatologie und Onkologie, München, 80639, Germany|MVZ Nordhausen gGmbH, Praxis Dr. Grafe, Nordhausen, 99734, Germany|Sana Klinikum Offenbach GmbH, Offenbach, 63069, Germany|St. Vincenz-Krankenhaus Paderborn, Paderborn, 33098, Germany|Oncologianova GmbH - Gesellschaft für Innovationen in der Onkologie, Recklinghausen, 45659, Germany|Klinikum am Steinenberg Frauenklinik, Reutlingen, 72764, Germany|Universitätsfrauen- und Poliklinik am Klinikum Suedstadt, Rostock, 18059, Germany|Gynäkologie Kompetenzzentrum, Stralsund, 18439, Germany|Robert-Bosch-Krankenhaus, Stuttgart, 70376, Germany|Gemeinschaftspraxis Dr. Kronawitter und Dr. Jung, Traunstein, 83278, Germany|Universitätsklinik Tübingen, Tübingen, 72076, Germany|Universitätsklinikum Ulm Am Michelsberg, Ulm, 89075, Germany|HELIOS Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, 65199, Germany|Marien-Hospital Witten, Witten, 58452, Germany|Hämatologisch-Onkologische Schwerpunktpraxis Dres. Schlag & Schöttker, Würzburg, 97080, Germany|Univ General Hosp Heraklion, Heraklion, 71110, Greece|Euromedical General Clinic of Thessaloniki, Thessaloniki, 54645, Greece|Grupo Angeles, Guatemala City, 01015, Guatemala|Centro Oncológico Sixtino / Centro Oncológico SA, Guatemala, 01009, Guatemala|Queen Mary Hospital, Hong Kong, 852, Hong Kong|Tuen Mun Hospital, Hong Kong, 852, Hong Kong|Pamela Youde Nethersole Eastern Hospital, Hong Kong, DUMMY_VALUE, Hong Kong|Cork Uni Hospital, Cork, DUMMY_VALUE, Ireland|St Vincent'S Uni Hospital, Dublin, 4, Ireland|Mater Misericordiae Uni Hospital, Dublin, 7, Ireland|Beaumont Hospital, Dublin, 9, Ireland|Galway Uni Hospital, Galway, DUMMY_VALUE, Ireland|University Hospital Limerick - Oncology, Limerick, DUMMY_VALUE, Ireland|Soroka Medical Center, Beer Sheva, 8410101, Israel|Shaare Zedek Medical Center, Jerusalem, 91031, Israel|Hadassah University Hospital - Ein Kerem, Jerusalem, 9112001, Israel|Rabin MC, Petach Tikva, 4941492, Israel|Sheba Medical Center, Ramat Gan, 52621, Israel|Kaplan Medical Center, Rehovot, 7610001, Israel|Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Campania, 80131, Italy|Università degli Studi Federico II, Napoli, Campania, 80131, Italy|Policlinico S.Orsola-Malpighi, Bologna, Emilia-Romagna, 40138, Italy|Ausl Di Bologna-Ospedale Bellaria, Bologna, Emilia-Romagna, 40139, Italy|Policlinico Universitario Campus Biomedico, Roma, Lazio, 00128, Italy|Az. Osp. Sant'Andrea, Roma, Lazio, 00189, Italy|IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST), Genova, Liguria, 16132, Italy|Asst Papa Giovanni XXIII, Bergamo, Lombardia, 24127, Italy|Asst Di Cremona, Cremona, Lombardia, 26100, Italy|Irccs Ospedale San Raffaele, Milano, Lombardia, 20132, Italy|Irccs Istituto Nazionale Dei Tumori (Int), Milano, Lombardia, 20133, Italy|Istituto Europeo Di Oncologia, Milano, Lombardia, 20141, Italy|Asst Di Monza, Monza, Lombardia, 20052, Italy|Fondazione Del Piemonte Per L'oncologia IRCC Di Candiolo, Candiolo, Piemonte, 10060, Italy|Ospedale Antonio Perrino, Brindisi, Puglia, 72100, Italy|Azlenda Ospendaliero-Universitaria Pisana, Pisa, Toscana, 56100, Italy|Azienda usl 5 Di Pisa-Ospedale Di Pontedera, Pontedera, Toscana, 56025, Italy|IOV - Istituto Oncologico Veneto - IRCCS, Padova, Veneto, 35128, Italy|A.O.U.I. Verona-Ospedale Borgo Trento, Verona, Veneto, 37126, Italy|Hospital Angeles Metropolitano, Mexico City, Mexico CITY (federal District), 06760, Mexico|Médicos Especialistas en Cáncer SC, Aguascalientes, 20230, Mexico|Instituto Nacional de Cancerologia, Distrito Federal, 14080, Mexico|Nstituto Nacional de Ciancias Medicas Y Nutricion, Salvador Zubir, Mexico City, 14080, Mexico|Oaxaca Site Management Organization, Oaxaca, 68000, Mexico|The Panama Clinic, Panama City, 0832, Panama|Centro Oncologico America, Panama, 0834-02723, Panama|Hospital Nacional Carlos Alberto Seguin Escobedo-Essalud, Arequipa, 04001, Peru|Centro Medico Monte Carmelo, Arequipa, DUMMY_VALUE, Peru|Hospital IV Alberto Sabogal Sologuren, Bellavista, Callao 2, Peru|Hospital Nacional Guillermo Almenara Irigoyen, Lima, 13, Peru|Clinica San Borja, Lima, Lima 41, Peru|Institute for Oncology and Radiology of Serbia, Belgrade, 11000, Serbia|Cape Town Oncology Trials, Cape Town, 7570, South Africa|Medical Oncology Centre of Rosebank, Johannesburg, 2196, South Africa|Wits Donald Gordon Clinical Trial Centre, Parktown, DUMMY_VALUE, South Africa|Hopelands Cancer Centre, Pietermaritzburg, 3201, South Africa|Cancercare, Port Elizabeth, 6045, South Africa|Private Oncology Centre, Pretoria, 0081, South Africa|Hospital de Donostia, San Sebastian, Guipuzcoa, 20080, Spain|Complexo Hospitalario de Vigo. Hospital Álvaro Cunqueiro, Vigo, Pontevedra, 36312, Spain|Hospital Universitari Sant Joan de Reus, Reus, Tarragona, 43204, Spain|Hospital Clínic i Provincial, Barcelona, 08036, Spain|Hospital Universitario La Paz, Madrid, 28046, Spain|Hospital de Madrid Norte Sanchinarro- Centro Integral Oncologico Clara Campal, Madrid, 28050, Spain|Hospital Regional Universitario Carlos Haya, Malaga, 29010, Spain|Hospital de Navarra, Navarra, 31008, Spain|Hospital Clinico Universitario de Salamanca, Salamanca, 37007, Spain|Hospital Universitario Virgen del Rocio, Sevilla, 41013, Spain|Instituto Valenciano Oncologia, Valencia, 46009, Spain|Hospital Universitario Dr. Peset, Valencia, 46017, Spain|Gävle Sjukhus, Gävle, 801 87, Sweden|Skånes University Hospital, Skånes Department of Onclology, Lund, 22185, Sweden|Karolinska Hospital, Stockholm, 17176, Sweden|Kantonsspital Aarau AG Medizin Onkologie, Aarau, 5001, Switzerland|Brust-Zentrum Zürich AG Seefeldstrasse 214 Zürich, Zürich, 8008, Switzerland|Taichung Veterans General Hospital, Taichung, 407, Taiwan|Veterans General Hospital, Taipei, 00112, Taiwan|National Taiwan Uni Hospital, Taipei, 100, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center, Taipei, 112, Taiwan|Chang Gung Medical Foundation - Linkou, Taoyuan, 333, Taiwan|Uludag Uni Hospital, Bursa, 16059, Turkey|Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department, Edirne, 22770, Turkey|Kartal Dr Lutfi Kirdar Sehir Hastanesi, Istanbul, 34000, Turkey|Ege Uni Medical Faculty Hospital, Izmir, 35100, Turkey|Inonu University Medical Faculty Turgut Ozal Medical Center Medical Oncology Department, Malatya, 44280, Turkey|University Hospital Birmingham The Cancer Centre, Queen Elizabeth Hospital, Birmingham, B15 2TH, United Kingdom|Bradford Royal Infirmary, Bradford, BD9 6RJ, United Kingdom|Bristol Haematology and Oncology centre, Bristol, BS2 8ED, United Kingdom|Castle Hill Hospital, Cottingham, HU16 5JG, United Kingdom|North Devon District Hospital, Devon, EX31 4JB, United Kingdom|Ninewells Hospital, Dundee, DD1 9SY, United Kingdom|Huddersfield Royal Infirmary, Huddersfield, HD3 3EA, United Kingdom|Leeds Teaching Hosp NHS Trust, Leeds, LS9 7TF, United Kingdom|St Thomas Hospital, London, SE1 7EH, United Kingdom|Christie Hospital Nhs Trust, Manchester, M2O 4BX, United Kingdom|Nottingham City Hospital, Nottingham, NG5 1PB, United Kingdom|Weston Park Hospital, Sheffield, S10 2SJ, United Kingdom|Royal Cornwall Hospital, Truro, TR1 3LJ, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/72/NCT01772472/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/72/NCT01772472/SAP_001.pdf"
